SRC-3 gene elimination in immune cells triggers effective long-lasting anti-cancer response
Written By : Isra Zaman
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-05-31 04:00 GMT | Update On 2023-05-31 04:00 GMT
Advertisement
Published in the Proceedings of the National Academy of Sciences, recent study shows that in animal models of breast and prostate cancer, eliminating the gene SRC-3, specifically in a type of immune cell called regulatory T cells (Tregs), triggered a lifelong anti-cancer response that eradicated the tumor without the typical side effects observed with other therapies. Furthermore, transferring Tregs without SRC-3 to animals carrying breast cancer tumors also resulted in long-term elimination of the tumor without negative side effects.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.